IRWD (Ironwood Pharmaceuticals) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRWD Ironwood Pharmaceuticals Inc IRWD
65 GF Score
Price $4.12
GF Value $4.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ironwood Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Ironwood Pharmaceuticals Quality Rank Related Terms

IRWD
65GF Score
Ironwood Pharmaceuticals Inc IRWD
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?

Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued. The current stock price of $4.12 is trading 9.5% below its estimated GF Value™ of $4.55. GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.

Key valuation signals for IRWD:

  • Quality Rank:
  • GF Value™: $4.55 vs. price of $4.12 (9.5% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ironwood Pharmaceuticals Business Description

Other Exchanges I76:Germany
Address 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score

Get the complete analysis for IRWD

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price
$4.55
GF Value